TY - JOUR
T1 - Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines
AU - Black, Steven
AU - Eskola, Juhani
AU - Siegrist, Claire Anne
AU - Halsey, Neal
AU - MacDonald, Noni
AU - Law, Barbara
AU - Miller, Elizabeth
AU - Andrews, Nick
AU - Stowe, Julia
AU - Salmon, Daniel
AU - Vannice, Kirsten
AU - Izurieta, Hector S.
AU - Akhtar, Aysha
AU - Gold, Mike
AU - Oselka, Gabriel
AU - Zuber, Patrick
AU - Pfeifer, Dina
AU - Vellozzi, Claudia
N1 - Funding Information:
SB serves on a data monitoring safety board for pneumococcal conjugate vaccine for GSK and has received honoraria for participation in scientific advisory boards for Novartis. NH has grants from the Centers for Disease Control and Prevention (CDC) to study adverse events after vaccination. He also serves on data safety review committees for clinical trials sponsored by CDC, Merck, and Novartis. C-AS has received honoraria for participation in scientific advisory boards and research grants from GSK, Wyeth, and Sanofi Pasteur. All other authors declare that they have no conflicts of interest.
PY - 2009
Y1 - 2009
N2 - Because of the advent of a new influenza A H1N1 strain, many countries have begun mass immunisation programmes. Awareness of the background rates of possible adverse events will be a crucial part of assessment of possible vaccine safety concerns and will help to separate legitimate safety concerns from events that are temporally associated with but not caused by vaccination. We identified background rates of selected medical events for several countries. Rates of disease events varied by age, sex, method of ascertainment, and geography. Highly visible health conditions, such as Guillain-Barré syndrome, spontaneous abortion, or even death, will occur in coincident temporal association with novel influenza vaccination. On the basis of the reviewed data, if a cohort of 10 million individuals was vaccinated in the UK, 21·5 cases of Guillain-Barré syndrome and 5·75 cases of sudden death would be expected to occur within 6 weeks of vaccination as coincident background cases. In female vaccinees in the USA, 86·3 cases of optic neuritis per 10 million population would be expected within 6 weeks of vaccination. 397 per 1 million vaccinated pregnant women would be predicted to have a spontaneous abortion within 1 day of vaccination.
AB - Because of the advent of a new influenza A H1N1 strain, many countries have begun mass immunisation programmes. Awareness of the background rates of possible adverse events will be a crucial part of assessment of possible vaccine safety concerns and will help to separate legitimate safety concerns from events that are temporally associated with but not caused by vaccination. We identified background rates of selected medical events for several countries. Rates of disease events varied by age, sex, method of ascertainment, and geography. Highly visible health conditions, such as Guillain-Barré syndrome, spontaneous abortion, or even death, will occur in coincident temporal association with novel influenza vaccination. On the basis of the reviewed data, if a cohort of 10 million individuals was vaccinated in the UK, 21·5 cases of Guillain-Barré syndrome and 5·75 cases of sudden death would be expected to occur within 6 weeks of vaccination as coincident background cases. In female vaccinees in the USA, 86·3 cases of optic neuritis per 10 million population would be expected within 6 weeks of vaccination. 397 per 1 million vaccinated pregnant women would be predicted to have a spontaneous abortion within 1 day of vaccination.
UR - http://www.scopus.com/inward/record.url?scp=72049119602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72049119602&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(09)61877-8
DO - 10.1016/S0140-6736(09)61877-8
M3 - Article
C2 - 19880172
AN - SCOPUS:72049119602
SN - 0140-6736
VL - 374
SP - 2115
EP - 2122
JO - The Lancet
JF - The Lancet
IS - 9707
ER -